Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Tecan Shows Ongoing Commitment to Clinical and Research Markets in China

Published: Monday, June 24, 2013
Last Updated: Monday, June 24, 2013
Bookmark and Share
Key opinion leaders from major hospital clinical laboratories in China recently visited Tecan’s European research and development centers.

The two-day program included a series of presentations and interactive workshops – as well as tours of Tecan’s research and manufacturing facilities in both Männedorf, Switzerland, and Grödig, Austria – and was intended to help guide the future development of Tecan laboratory automation solutions for this fast-growing market.

The visit began at Tecan’s global headquarters on the shores of Lake Zurich, with a presentation and demonstration of a Freedom EVO workstation configured for ELISA processing. This system, developed as part of an ongoing collaboration with hospitals and blood centers across China, introduces a number of unique features designed specifically to meet the requirements of the Chinese clinical market. The latest developments for this exciting project include a number of options to increase throughput and ease-of-use, such as a Chinese language version of the recently released TouchTools™ 3.0 touchscreen user interface. Sample and process security has been further enhanced with the addition of Tecan’s unique QC Kit, which provides liquid handling performance verification and reporting to comply with stringent regulations. Visitors were also given the opportunity to outline their current hospital laboratory practices and likely future requirements, helping to ensure that future clinical solutions are tailored to the exact needs of end-users.

The Austrian leg of the tour included presentation of a number of detection solutions to meet various aspects of clinical and research laboratory workflows, as well as interactive workshops to help shape future development of detection instruments and software for the Asian research market. Customers were introduced to a number of solutions from Tecan’s detection portfolio, including cost-effective instruments for routine ELISA processing – such as the Infinite F50 ELISA reader and Sunrise™ absorbance reader – and state-of-the-art multimode readers, such as the Infinite M1000 PRO. Delegates were given a demonstration of the Infinite M1000 PRO’s advanced assay development capabilities, combining premium Quad4 Monochromators™ optics with a range of advanced software features – such as luminescence scanning capabilities – to provide unlimited flexibility in assay design. The versatility of the Infinite M200 PRO was also highlighted during the visit, showcasing both the unrivalled cell-based assay performance of the system’s Gas Control Module (GCM™) and the low volume DNA quantification capabilities of Tecan’s unique NanoQuant Plate™. The trip was rounded off with a brief introduction to some of the vibrant history and culture of both Salzburg and Vienna, giving delegates a chance to take a mix of fond memories and innovative ideas back to their own laboratories.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!